Walczuk, S.; Cunningham, F.E.; Zhao, X.; Dong, D.; Glassman, P.A.; Miller, D.R.; Khachikian, D.; Au, A.; Salone, C.; Bryan, K.;
et al. Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration. Pharmacoepidemiology 2024, 3, 103-116.
https://doi.org/10.3390/pharma3010008
AMA Style
Walczuk S, Cunningham FE, Zhao X, Dong D, Glassman PA, Miller DR, Khachikian D, Au A, Salone C, Bryan K,
et al. Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration. Pharmacoepidemiology. 2024; 3(1):103-116.
https://doi.org/10.3390/pharma3010008
Chicago/Turabian Style
Walczuk, Samantha, Francesca E. Cunningham, Xinhua Zhao, Diane Dong, Peter A. Glassman, Donald R. Miller, Deborah Khachikian, Anthony Au, Cedric Salone, Kelly Bryan,
and et al. 2024. "Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration" Pharmacoepidemiology 3, no. 1: 103-116.
https://doi.org/10.3390/pharma3010008
APA Style
Walczuk, S., Cunningham, F. E., Zhao, X., Dong, D., Glassman, P. A., Miller, D. R., Khachikian, D., Au, A., Salone, C., Bryan, K., Her, Q., & Aspinall, S. L.
(2024). Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration. Pharmacoepidemiology, 3(1), 103-116.
https://doi.org/10.3390/pharma3010008
